Skip to content

Rechercher des études

Résultats de recherche

Timely and safe extubation in critically ill patients is vitally important as prolonged mechanical ventilation and failed attempts at extubation are associated with increased morbidity, mortality, costs, intensive care unit (ICU) stays, and a risk for aerosolization of COVID-19 to health care providers. A Spontaneous Breathing Trial (SBT) is the current standard of care to assess a patient's readiness for extubation. However, SBTs are performed in various ways and have poor ability to predict successful extubation on their own. There is an urgent need to improve and standardize extubation decision-making. In a prior multicenter study, the investigators showed that decreased respiratory rate variability during SBTs predicted extubation failure better than other predictive indices. The Extubation Advisor (EA) tool combines clinician's assessments of extubation readiness with predictive analytics and risk mitigation strategies for individual patients. In a single centre observational study, the investigators demonstrated the ability to deliver EA reports to the bedside and acceptability of this decision-support tool to respiratory therapists (RTs) and physicians (MDs). The investigators will conduct the Liberation from mechanical ventilation using EA Decision Support (LEADS) Pilot Trial to assess feasibility outcomes. They will include critically ill adults who are invasively ventilated for \>48 hours and are ready to undergo an SBT. Patients in the intervention arm undergo an EA assessment and treating clinicians (RTs, MDs) will receive an EA report for each SBT conducted. The EA report will help to guide extubation decision-making. Patients in the control arm receive standard care. SBTs will be directed by clinicians. The primary feasibility outcome will reflect the ability to recruit the desired population. The investigators will also assess the usefulness of the tool to MDs and complete an analysis of resource utilization to inform future economic analyses of cost-effectiveness. The investigators aim to recruit 1 to 2 patients/month/center. The LEADS trial is novel and low-risk. It is the first trial to evaluate use of a bedside decision support tool to assist ICU clinicians with extubation decision-making. The LEADS pilot trial will inform the design of a future, large-scale randomized controlled trial that is expected to enhance the care delivered to critically ill patients, improve extubation outcomes, and inform extubation practice in ICUs.

Conditions:
Airway Extubation
Emplacement:
  • Unity Health Toronto - St. Michael's Hospital, Toronto, Ontario, Canada
  • Queensway Carleton Hospital, Ottawa, Ontario, Canada
  • Kingston Health Sciences Centre, Kingston, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada
  • The Ottawa Hospital, Ottawa, Ontario, Canada
Sexe:
ALL
Âges:
Over 18

The Positively Dance study involves the assessment of the accessibility and feasibility of a 12-week randomized aerobic dance pilot program that will provide women living with HIV with the opportunity to take part in dance classes with women living with HIV as the dance instructors.

Conditions:
Human Immunodeficiency Virus
Emplacement:
  • University of British Columbia, Vancouver, British Columbia, Canada
Sexe:
ALL
Âges:
Over 18

The FAST Trial Registry is a prospective observational cohort study of fetuses with a new diagnosis of atrial flutter (AF) or supraventricular tachycardia (SVT) that is severe enough to consider prenatal treatment (see eligibility criteria below). Aims of the Registry include to establish a large clinical database to determine and compare the efficacy and safety of different prenatal treatment strategies including observation without immediate treatment, transplacental antiarrhythmic fetal treatment and direct fetal treatment from the time of tachycardia diagnosis to death, neonatal hospital discharge or to a maximum of 30 days after birth.

Conditions:
Tachycardia, Supraventricular | Atrial Flutter | Fetal Hydrops | Tachycardia, Atrioventricular Nodal...
Emplacement:
  • London Health Sciences Centre, London, Ontario, Canada
  • Alberta Children's Hospital, Calgary, Ontario, Canada
  • CHU Saine-Justine, Montréal, Quebec, Canada
  • University of Alberta, Edmonton, Alberta, Canada
  • The Hospital for Sick Children, Toronto, Ontario, Canada
  • The U of British Columbia, Vancouver, British Columbia, Canada
  • Mount Sinai Hospital, Toronto, Ontario, Canada
Sexe:
FEMALE
Âges:
16 - 50

High-intensity interval exercise (HIIE) is a type of exercise that involves alternating periods of intense exercise with periods of rest. HIIE has been shown to improve many aspects of cardiovascular and metabolic health in a time-efficient manner (e.g., only 20 minutes per exercise session). An important health benefit of exercise is improved blood sugar control, which can help reduce the risk of metabolic diseases like type 2 diabetes. A single session of HIIE has been shown to improve blood sugar in males, but it is unknown if females achieve the same health benefit. It is also not fully understood how exercise improves blood sugar in males and females. Therefore, the purpose of this project is 1) to determine if a single session of HIIE improves blood sugar control in males and females, and 2) to evaluate if changes in skeletal muscle can explain the beneficial effects of HIIE on blood sugar.

Conditions:
Exercise
Emplacement:
  • Goldring Centre for High Performance Sport, Toronto, Ontario, Canada
Sexe:
ALL
Âges:
18 - 35

The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a high-fidelity prospective multi-centre registry. The study population consists of consecutive adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data are captured in real time by a full-time third-party research assistant directly observing procedures. Outcomes are ascertained by comprehensive medical record review and patient phone interview 30 days after the index procedure. This registry also serves as a secure data collection platform for several currently recruiting prospective studies and randomized trials.

Conditions:
Pancreatic Diseases | Biliary Disease
Emplacement:
  • University of Calgary, Calgary, Alberta, Canada
Sexe:
ALL
Âges:
Over 18

"Health is a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity" (World Health Organization, 1948). Diseases such as HIV/AIDS and Hepatitis-C (HCV) thrive in conditions of poverty and marginalization. Research on the quality of life of people living with HIV/AIDS reveals that unemployed individuals report more depression, anxiety, social isolation, and low self-esteem than employed individuals. Moreover, unemployment is a key factor in the contemplation of suicide among people with HIV/AIDS. Alternatively, employment among people living with HIV/AIDS is a strong indicator of improved quality of life. A finding the study investigators confirmed in a research study (PROMPT) supporting 280 members of Ottawa's low income homeless (or at-risk for homelessness) People Who Use Drugs reduce (and in some cases quit) smoking. PROMPT participants repeatedly stated that boredom and a lack of meaningful social connections and employment were major hindrances in their reduction and overall recovery from smoking and drug use. With these PROMPT findings, the investigators propose a Community-Based Participatory Action project that builds the social capital of 80 participants that identify as members of Ottawa and Toronto's low income People Who Use drugs living with or are at-risk for HIV/AIDS/HCV. The proposed multi-site project will include life-skills training, counseling, health services access (testing and treatment), and education on HIV/AIDS/HCV. Most importantly the project will include a poverty reduction intervention that connects participants with education opportunities, short-term work and volunteer opportunities. The education, work and volunteer opportunities' will be made possible with the support of local business owners and networks that support the study's poverty reduction and community building elements. The aim of project will be to demonstrate the feasibility and cost of a holistic healthcare that encourages a state of complete physical, mental, and social well-being.

Conditions:
Substance Use Disorders | Nicotine Dependence
Emplacement:
  • The Bridge Engagement Centre, Ottawa, Ontario, Canada
Sexe:
ALL
Âges:
16 - 80

Anterior vertebral body tethering (AVBT) is a novel, minimally invasive, growth modulation technique that was recently approved by the FDA under a Humanitarian Device Exemption (HDE). The goal of AVBT is to control curve progression by applying compression on the convex side of the spine deformity. While there has been great initial enthusiasm about the technique as an alternate treatment option to spinal fusion for skeletally immature children with scoliosis, there is a need to better understand the long-term outcomes. The purpose of this study is to report the long-term clinical outcomes of skeletally immature patients treated with AVBT, specifically: 1. The effect on three-dimensional spine growth as compared to normal controls 2. Maintenance of major Cobb angle less than or equal to 50 degrees at skeletal maturity 3. Complications associated with both the procedure and the device

Conditions:
Scoliosis Idiopathic
Emplacement:
  • Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Sexe:
ALL
Âges:
Under 18

This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.

Conditions:
Cancer | Cancer, Therapy-Related | Malignant Solid Tumor | Malignancies Multiple | Molecular Sequence...
Emplacement:
  • Tom Baker Cancer Centre - University of Calgary - Alberta Health Services, Calgary, Alberta, Canada
  • Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada
  • Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada
  • Health Sciences North, Sudbury, Ontario, Canada
  • Sunnybrook Research Institute - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  • McGill University Health Centre, Montréal, Quebec, Canada
  • Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada
  • CancerCare Manitoba/University of Manitoba, Winnipeg, Manitoba, Canada
  • William Osler Health System - Brampton Civic Hospital, Brampton, Ontario, Canada
  • Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
  • Mount Sinai Hospital, Toronto, Ontario, Canada
  • Jewish General Hospital, Montréal, Quebec, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, Quebec, Canada
  • Cross Cancer Institute, University of Alberta - Alberta Health Services, Edmonton, Alberta, Canada
  • Dr. H. Bliss Murphy Cancer Centre, Saint John's, Newfoundland and Labrador, Canada
  • Kingston Health Sciences Centre (KHSC), Kingston, Ontario, Canada
  • Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada
  • St. Mary's Hospital Center, Montréal, Quebec, Canada
  • Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
  • BC Cancer, Vancouver, British Columbia, Canada
  • Queen Elizabeth II (QEII) Health Sciences Centre, Halifax, Nova Scotia, Canada
  • Lawson Health Research Institute - London Health Sciences Centre, London, Ontario, Canada
  • Princess Margaret Cancer Centre (PMCC) - University Health Network (UHN), Toronto, Ontario, Canada
  • Hôpital du Sacré-Coeur-de-Montréal (HSCM), Montréal, Quebec, Canada
  • Centre hospitalier de l'université de Québec - Université Laval, Québec City, Quebec, Canada
  • Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
Sexe:
ALL
Âges:
Over 18

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Emplacement:
  • Research Site, Kamloops, British Columbia, Canada
  • Research Site, Guelph, Ontario, Canada
  • Research Site, Winchester, Ontario, Canada
  • Research Site, Sherwood Park, Alberta, Canada
  • Research Site, Barrie, Ontario, Canada
  • Research Site, Stouffville, Ontario, Canada
  • Research Site, Calgary, Alberta, Canada
  • Research Site, Kelowna, British Columbia, Canada
  • Research Site, Hamilton, Ontario, Canada
  • Research Site, Montreal, PQ, Canada
  • Research Site, Edmonton, Alberta, Canada
  • Research Site, Ajax, Ontario, Canada
  • Research Site, Markham, Ontario, Canada
  • Research Site, Terrebonne, Quebec, Canada
Sexe:
ALL
Âges:
40 - 130

This study aims to evaluate the impact of Transanal irrigation (TAI) on the quality of life and low anterior resection symptoms (LARS) in Canadian rectal cancer survivors living with minor to major LARS. It proposes to teach TAI through a novel online platform and to provide virtual nursing support for the participants. To our knowledge, this is the first North American based and largest randomized control trial on the use of TAI for patients with LARS. This will also be the first study to teach and support patients through the TAI process using a virtual platform. While TAI has been demonstrated to reduce LARS scores and increased QoL in patients with significant LARS, its feasibility and acceptance for Canadian patients remains uncertain. Furthermore despite the existing studies, the rate of TAI seems to be low in North America. The hypothesis is that TAI, taught and supported through an online portal dedicated to LARS patients, will positively impact QoL and improve LARS symptoms. The results of this trial may allow TAI to become part of the standard armamentarium that clinicians offer patients for LARS management, with the presence of online nursing support and guidance to facilitate this practice.

Conditions:
Rectal Cancer | Low Anterior Resection Syndrome
Emplacement:
  • Jewish General Hospital, Montreal, Quebec, Canada
  • McGill University Health Centre, Montréal, Quebec, Canada
Sexe:
ALL
Âges:
Over 18